Comparative Pharmacology
Head-to-head clinical analysis: RAUWOLFIA SERPENTINA versus SERPIVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUWOLFIA SERPENTINA versus SERPIVITE.
RAUWOLFIA SERPENTINA vs SERPIVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
None Documented
None Documented
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5%
Category C
Category C
Antihypertensive
Antihypertensive